We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Ian
Bruce
ian.bruce@manchester.ac.uk
Mrs
Fiona
Stirling
fiona.stirling@manchester.ac.uk
Inflammatory polyarthropathiesSystemic connective tissue disordersPapulosquamous disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Working with the NIHRBR, we are proposing to develop a centralised national recallable bioresource of 16,000 patients and relatives of patients with one or more of a spectrum of disorders which comprise immune-mediated inflammatory diseases (IMIDs), to support scientific and clinical IMID research.
1. DNA and serum + clinical and genetic data from 16,000 IMID patients and relatives recruited England-wide stored in a central biorepository funded by NIHR BioResource
2. Stratify participants into core datasets for analysis
3. Recallability - run by NIHRBR National Co-ordinating Centre, allowing patients stratified by clinical subtype or comorbidities to be recruited for future scientific or clinical trials (with additional approvals and consent)
Immune-mediated inflammatory diseases (IMIDs) are a spectrum of disorders with shared susceptibility genes, overlapping ways in which the immune response is developed, clinical features and comorbidities. However each disease also has unique disease-specific pathways in which they develop. Some treatments are effective against all these diseases, however others are not and can paradoxically make the condition worse. Learning about how these mechanisms work will help to target effective therapies to each specific disease area.
IMID BioResource will focus on 3 pivotal IMIDs and 3 cross-cutting co-morbidities:
• Rheumatoid Arthritis (RA)
• Psoriasis (and the linked seronegative spondyloarthropathies family)
• SLE and related syndromes: mixed and undifferentiated connective tissue diseases (MCTD and UCTD)
Cross-cutting co-morbidity phenotypes will initially focus on
• Chronic lung disease including COPD and Interstitial lung disease (ILD)
• Cardiovascular disease (CVD)
• Fatigue/mood disorders
The NIHRBR-IMID will be managed by a partnership across the 3 Northern Biomedical Research Centres (BRCs) (Manchester, Newcastle and Leeds) and co-ordinated from Manchester BRC. NIHRBR-IMID reflects common and overlapping areas in which all three partners demonstrate (inter)national leadership and expertise. Strategically NIHRBR-IMID will complement and synergise with existing BioResource supported diseases including a number of Rare Diseases.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
There will be no exclusion on the basis of sex, ethnicity, religion or sexual orientation. Participants with mental and learning disabilities are included provided they are deemed competent to consent. Adults lacking capacity will be excluded. Patients will be excluded if they are not willing or able to be notified of and recalled for future studies. For participants who may not adequately understand verbal explanations or written information in English, an interpreter will be used where possible. Children under the age of 16 will be excluded
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by MANCHESTER UNIVERSITY NHS FOUNDATION TRUST and funded by NATIONAL INSTITUTE FOR HEALTH AND CARE RESEARCH .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 44431
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
